This is a pilot, multinational, multicenter, randomized, double-blind, placebo-controlled, safety and efficacy study. Subjects will consist of males or females 18 to 85 years of age hospitalized for ADHF with persistent hypotension (systolic blood pressure [SBP] 75 to 90 mmHg for two hours), and heart rate 75 to 150 beats/minute.~Subjects will be enrolled into one of two groups in a 1:1 ratio: istaroxime or matching placebo, administered via 24-hour intravenous (IV) infusion. Istaroxime administration can begin at 1.0 or 1.5 µg/kg/min; the target infusion rate is 1.5 µg/kg/min. All subjects will receive standard of care.~Approximately 30 sites from North America, South America, Europe, and/or Asia will participate in this study.
This is a pilot, multinational, randomized, double-blind, placebo-controlled safety and efficacy study. Subjects will consist of patients hospitalized for acute decompensated heart failure with persistent hypotension and heart rate 75 to 150 beats/minute.